

successor in interest to the Federal Savings and Loan Insurance Corporation as receiver for Butterfield Savings and Loan Association, Santa Ana, California, has determined that the proceeds which can be realized from the liquidation of the assets of the receivership estate are insufficient to allow a dividend, distribution or payment to any holder of a claim or equity interest. Therefore, any such claims or interests are hereby determined to be worthless.

**FOR FURTHER INFORMATION CONTACT:** Thomas Bolt, Counsel, Legal Division, FDIC, 550 17th Street, NW., Room H-11048, Washington, DC 20429. Telephone: (202) 736-0168.

Dated: March 18, 1997.

**Robert E. Feldman,**  
Deputy Executive Secretary.  
[FR Doc. 97-7326 Filed 3-21-97; 8:45 am]  
BILLING CODE 6714-01-P

### Sunshine Act Meeting; Notice of a Matter To Be Withdrawn From the Agenda for Consideration at an Agency Meeting

Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that the following matter will be withdrawn from the "discussion agenda" for consideration at the open meeting of the Board of Directors of the Federal Deposit Insurance Corporation scheduled to be held at 10:00 a.m. on Tuesday, March 25, 1997, in the Board Room on the sixth floor of the FDIC Building located at 550 17th Street, N.W., Washington, D.C.:

Memorandum and resolution re:

Proposed Rule Regarding Deposit Insurance Simplification.

Requests for further information concerning the meeting may be directed to Mr. Robert E. Feldman, Deputy Executive Secretary of the Corporation, at (202) 898-6757.

Dated: March 20, 1997.

Federal Deposit Insurance Corporation  
**Robert E. Feldman,**  
Deputy Executive Secretary.  
[FR Doc. 97-7481 Filed 3-20-97; 2:13 pm]  
BILLING CODE 6714-01-M

### FEDERAL RESERVE SYSTEM

#### Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12

CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than April 7, 1997.

**A. Federal Reserve Bank of Minneapolis** (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. *Theodore J. Hofer*, Freeman, South Dakota, to acquire an additional 3.4 percent, for a total of 35.8 percent, of the voting shares of H & W Holding Company, Freeman, South Dakota, and thereby indirectly acquire Merchants State Bank, Freeman, South Dakota.

**B. Federal Reserve Bank of Kansas City** (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Morris Mayer Testamentary Trust, Dale Walkenhorst as Trustee*, Madison, Nebraska, to acquire 26.91 percent of the voting shares of Madison Bancshares, Inc., Madison, Nebraska, and thereby indirectly acquire Bank of Madison, Madison, Nebraska.

**C. Federal Reserve Bank of Dallas** (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Donald Edward Powell*, Amarillo, Texas, to acquire 100 percent of the voting shares of Tejas Bancshares, Inc., Fritch, Texas, and thereby indirectly acquire Fritch State Bank, Fritch, Texas.

Board of Governors of the Federal Reserve System, March 18, 1997.

**Jennifer J. Johnson,**  
Deputy Secretary of the Board.  
[FR Doc. 97-7298 Filed 3-21-97; 8:45 am]  
BILLING CODE 6210-01-F

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Notice of Four Meetings of the National Bioethics Advisory Commission (NBAC)

**SUMMARY:** Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of four meetings of the National Bioethics Advisory Commission. The

Commission will continue discussing its response to the President's request to review the legal and ethical implications of the possible cloning of humans following the discovery of a technique for cloning sheep. The Commission is to report to the President in late May. This scientific finding raises a host of issues including ethical questions, in particular, the possible use of this technique to clone human embryos, as well as the promise of benefits in a number of areas. The meetings are open to the public and opportunities for statements by the public will be provided.

#### Dates/Times/Locations

Sunday, April 13, 1997, 7:30 a.m.-3:30 p.m.—Crystal City Marriott, 1999 Jefferson Davis Highway, Arlington, VA. 22202

Friday, May 2, 1997, 7:30 a.m.-3:30 p.m.—Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, VA. 22202

Saturday, May 17, 1997, 7:30 a.m.-3:30 p.m.—Crystal City Marriott, 1999 Jefferson Davis Highway, Arlington, VA. 22202

Saturday, June 7, 1997, 7:30 a.m.-3:30 p.m.—Crystal City Marriott, 1999 Jefferson Davis Highway, Arlington, VA. 22202

**SUPPLEMENTARY INFORMATION:** The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975 on October 3, 1995. The general mission of the NBAC is to advise and make recommendations to the National Science and Technology Council and other entities on bioethical issues arising from the research on human biology and behavior, and in the applications of that research including clinical applications. On the issue of cloning, the Commission is to undertake a thorough review of the legal and ethical issues associated with the use of this technology, and report back to the President with recommendations on possible federal actions to prevent its abuse.

#### Tentative Agenda

The Commission will continue its review of the legal and ethical issues associated with the possible cloning of human beings and may hear from a number of invited speakers who are experts in their fields. Because of the very short lead time, more details are not yet available. Agendas will be available shortly before each meeting (see details below).

#### Public Participation

The meetings are open to the public with attendance limited by the